These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 12142632)
21. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741 [TBL] [Abstract][Full Text] [Related]
22. Effect of time of dosing on the disposition of oral cibenzoline. Brazzell RK; Khoo KC; Schneck DW Biopharm Drug Dispos; 1985; 6(4):433-40. PubMed ID: 4084668 [TBL] [Abstract][Full Text] [Related]
23. Long-term impact of therapeutic drug monitoring on the risk of hypoglycemia in HOCM patients on cibenzoline therapy . Mukai Y; Wada K; Fujimoto M; Hosomi K; Kuwahara T; Takada M Int J Clin Pharmacol Ther; 2016 Oct; 54(10):795-803. PubMed ID: 27443663 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of intravenous cibenzoline in normal volunteers. Brazzell RK; Khoo KC; Szuna AJ; Sandor D; Aogaichi K; Wills RJ J Clin Pharmacol; 1985 Sep; 25(6):418-23. PubMed ID: 4056077 [TBL] [Abstract][Full Text] [Related]
32. The electrophysiologic effects of oral cibenzoline. Kushner M; Magiros E; Peters R; Carliner N; Plotnick G; Fisher M J Electrocardiol; 1984 Jan; 17(1):15-23. PubMed ID: 6199450 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of cibenzoline after single and repetitive dosing in healthy volunteers. Massarella JW; Khoo KC; Szuna AJ; Sandor DA; Morganroth J; Aogaichi K J Clin Pharmacol; 1986 Feb; 26(2):125-30. PubMed ID: 3950056 [TBL] [Abstract][Full Text] [Related]
34. A case of severe respiratory depression due to cibenzoline overdosage induced by a transient renal dysfunction. Inada K; Sekita G; Sawaki D; Otani Y; Fukushima K; Takeuchi H; Aoyagi T Int J Cardiol; 2002 Feb; 82(2):177-8. PubMed ID: 11853904 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. Takabatake T; Ohta H; Yamamoto Y; Ishida Y; Hara H; Ushiogi Y; Nakamura S; Hashimoto N; Sasaki T; Satoh S Eur J Clin Pharmacol; 1991; 40(4):411-4. PubMed ID: 2050177 [TBL] [Abstract][Full Text] [Related]
36. Hemodynamic effects of a new antiarrhythmic agent: cibenzoline. Rigaud M; Jouret G; Canal M; Bardet J; Flouvat B; Bourdarias JP J Pharmacol; 1985; 16(3):247-57. PubMed ID: 4068726 [TBL] [Abstract][Full Text] [Related]
37. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. Corey AE; Agnew JR; Valentine SN; Parekh NJ; Powell JH; Thompson GA Br J Clin Pharmacol; 2002 Nov; 54(5):449-52. PubMed ID: 12445022 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic evaluation of a case of massive sotalol intoxication. Gustavsson CG; Vinge E; Norlander BO; Pantev E Ann Pharmacother; 1997; 31(7-8):856-9. PubMed ID: 9220045 [TBL] [Abstract][Full Text] [Related]
39. Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias. Harron DW; Brogden RN; Faulds D; Fitton A Drugs; 1992 May; 43(5):734-59. PubMed ID: 1379150 [TBL] [Abstract][Full Text] [Related]